Kubota Pharmaceutical Holdings Co., Ltd.
https://www.kubotaholdings.co.jp/en
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Kubota Pharmaceutical Holdings Co., Ltd.
Multiple Stargardt Contenders Progress In Japan Despite Small Market
With no approved therapies globally for Stargardt's, competition in the indication is increasing in Japan, where Kubota Vision is seeking for conditional approval for emixustat, while Belite Bio’s contender tinlarebant has received Sakigake designation as a local Phase III program continues.
Japan Gene Therapies Progress In Post-Zolgensma World
The recent reimbursement and launch of Zolgensma showed Japan willing and able to approve and pay for gene therapies, and others including from Otsuka/Takara Bio are moving forward under a supportive regulatory framework.
Horama's Gene Therapies For Retinal Diseases: Fast Followers?
French biotech Horama has built-up its executive team and has two potential gene therapies for retinitis pigmentosa nearing the clinic.
Pipeline Watch: Phase III Trials For Daprodustat, Rovalpituzumab Tesirine
Pipeline Watch has been updated to bring greater depth and detail to a potential therapeutic product’s progress through the R&D pipeline. The table brings you a snapshot of selected late-stage clinical trial events in the pharma and biotech industries.
Company Information
- Industry
- Pharmaceuticals
-
Medical Devices
- Monitoring Equipment & Devices
-
Biotechnology
- Gene Therapy, Cell Therapy
- Other Names / Subsidiaries
-
- Acucela Japan Kabushiki Kaisha
- Acucela, Inc.
- Kubota Vision Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice